top of page

FDA temporarily lifts Juul ban

The FDA announced that its ban on Juul Labs’ products would be lifted while the e-cigarette maker appealed the agency's decision, allowing its ENDS products to return to store shelves.

A bit of background is necessary to

shed light on the ban itself. In August of 2016, the FDA’s Deeming Rule took effect, which applied many of the regulatory and statutory requirements that had been in place for manufacturers of cigarettes and tobacco to electronic nicotine delivery systems (ENDS) product manufacturers.


Prior to the deeming rule, vape and other ENDS products were virtually unregulated on a federal level. The Deeming rule subjects ENDS products to the Tobacco Control Act, including the requirement that a new tobacco product receive premarket authorization from the FDA prior to marketing. The FDA issued a compliance policy allowing manufacturers of existing ENDS products until September 9, 2020, to submit the necessary application for FDA review. Pursuant to the Tobacco Control Act, only ENDS products deemed "appropriate for the protection of public health" may be authorized by the FDA.


Last month, in response to Juul Labs’ applications, the FDA issued marketing denial orders (MDOs) for all of JUUL Labs products currently marketed in the U.S, citing a lack of sufficient evidence that they were safe. In short, the company was ordered to cease selling and distributing these products and remove those products currently on the market.


The next day, a federal appeals court granted Juul Labs a temporary stay of the order, and Juul filed to extend the stay during the appeal process. Juul had prior requested that the FDA stay its own order pending the appeal, which the FDA originally denied.

However, The FDA announced yesterday that its MDO on Juul Labs Inc. products would be lifted while the ENDS maker appealed the agency's decision. According to the agency, it had “determined that there are scientific issues unique to the JUUL application that warrant additional review." The administrative stay suspends the order temporarily during the additional review but does not rescind it.


The FDA has approved ENDS products from some of Juul's main competitors, such as NJOY Holdings Inc., and many industry participants expect that Juul will receive similar approval.


0 comments

Recent Posts

See All

Comments


© 2014-2024 by Dynamic Law Group PLLC. 

Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice on any matter. The transmission and receipt of information contained on this website or communication through this website does not constitute or create a lawyer-client relationship between Dynamic Law Group PLLC ("DLG") and any recipient. You should not send any confidential information in response to this webpage. Such responses will not create a lawyer-client relationship, and whatever you disclose to DLG will not be privileged or confidential unless DLG has agreed to act as your legal counsel and you have executed a written engagement agreement with DLG. The material on this website may not reflect the most current legal developments. The content and interpretation of the law addressed herein is subject to revision. We disclaim all liability in respect to actions taken or not taken based on any or all the contents of this site to the fullest extent permitted by law. Do not act or refrain from acting upon this information without seeking professional legal counsel.

View our PrivacyPolicy

 

  • Facebook Social Icon
  • LinkedIn Social Icon
  • Twitter Social Icon
bottom of page